Which is better, RMD or TBPH?

On the Buffett-Fit framework, ResMed Inc. (RMD) currently grades higher than TBPH — 72/100 (B grade) vs 53/100 (D). That said, "better" depends on which framework you trust — RMD wins on Warren Buffett, Benjamin Graham, Philip Fisher, Peter Lynch, Joel Greenblatt, Charlie Munger, and Terry Smith; TBPH wins on none. The full pillar breakdown is on this page.

Should I buy RMD or TBPH?

This page is an educational comparison, not investment advice. Both RMD and TBPH are graded against the same Buffett 5-pillar framework (moat, earnings durability, management quality, financial health, valuation) plus six other documented investor frameworks. Read the side-by-side breakdown to see which one matches the criteria you care about most — and always do your own research before making any investment decision.

Is RMD better than TBPH for value investing?

On the Buffett-style value-investing framework, RMD currently grades higher — 72/100 vs 53/100, a 19-point gap. The gap is driven by which pillars each stock passes; the table on this page shows moat, durability, management, financial health, and valuation side-by-side.

What's the difference between RMD and TBPH on Warren Buffett's framework?

Both stocks are evaluated on the same five pillars: economic moat (durable competitive advantage), earnings durability (consistent profitability), management quality (capital allocation), financial health (conservative balance sheet), and valuation (margin of safety). RMD currently scores 72/100 (B grade); TBPH scores 53/100 (D grade). The "Where each wins" section on this page breaks down which pillar each stock dominates.

Which has the stronger moat, RMD or TBPH?

Moat strength is one of the five pillars in the Buffett-Fit score on this page. RMD and TBPH are each scored on ROIC sustainability, gross-margin durability, and qualitative signals like brand strength, switching costs, network effects, and regulatory barriers. The pillar breakdown on this page shows the moat sub-score side-by-side so you can see which one has the more durable competitive advantage.

Which is more undervalued, RMD or TBPH?

Valuation is one of the five Buffett-Fit pillars on this page. Both stocks are scored on owner-earnings yield, price-to-intrinsic-value vs the underlying compounding rate, and the margin of safety relative to a conservative DCF. The valuation sub-score in the table below tells you which one currently trades at a more attractive price relative to its underlying business quality.

Are RMD and TBPH both Healthcare stocks?

Yes — both ResMed Inc. (RMD) and Theravance Biopharma, Inc. (TBPH) operate in the Healthcare sector. That makes this a direct sector-peer comparison, which is the apples-to-apples way to use the Buffett-Fit framework: the score weighs each stock against its sector's specific quality and valuation benchmarks (sector-relative bonus), so the cross-stock comparison isn't distorted by inter-sector base-rate differences.

Is this RMD vs TBPH comparison investment advice?

No. This page is an educational pattern-match against documented public frameworks (Buffett, Graham, Fisher, Lynch, Greenblatt, Munger, Smith), not personalised investment advice. The scores reflect how closely each stock matches each framework's documented criteria — they are not buy/hold/sell recommendations. Always do your own research and consult a licensed financial adviser for personalised advice.

Stock comparison

ResMed

Theravance Biopharma

Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.

RMD

ResMed

Market cap

$30.18B

Sector

Healthcare

TBPH

Theravance Biopharma

Market cap

$843.92M

Sector

Healthcare

Overall winner

ResMed RMD

Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.

Fit scores by strategy

Strategy	RMD	TBPH	Winner
Warren Buffett	72B	53D	RMD
Benjamin Graham	75B	51D	RMD
Philip Fisher	75B	45D	RMD
Peter Lynch	58C	53C	RMD
Joel Greenblatt	47D	36D	RMD
Charlie Munger	69B	39D	RMD
Terry Smith	73B	56C	RMD

Side-by-side metrics

Metric	RMD	TBPH
Market cap	$30.18B	$843.92M
P/E (TTM)	19.6x	7.4x
EV/EBIT	17.1x	-
ROIC (TTM)	19.63%	-1.32%
Gross margin	61.69%	104.1%
Net margin	27.44%	104.34%
Revenue CAGR 5y	12.64%	18.06%
EPS CAGR 5y	30.73%	-
Debt / Equity	0.1x	0.3x
Dividend yield	1.14%	0.0%

Where each one wins

The metrics with the biggest gap between the two - sorted so the most decisive edges read first.

RMD leads on

ROIC (TTM)19.63%vs -1.32%+107%
Dividend yield1.14%vs 0.0%+100%
Market cap$30.18Bvs $843.92M+97%
Debt / Equity0.1xvs 0.3x+49%

TBPH leads on

EV/EBIT-vs 17.1x+136%
Net margin104.34%vs 27.44%+74%
P/E (TTM)7.4xvs 19.6x+63%
Gross margin104.1%vs 61.69%+41%

Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.

ResMed

Theravance Biopharma

Fit scores by strategy

Side-by-side metrics

Where each one wins

More like RMD

More like TBPH

Related on invest-like

Key terms in this analysis